Last updated: April 8, 2024
Sponsor: Queen Mary Hospital, Hong Kong
Overall Status: Active - Recruiting
Phase
N/A
Condition
Venous Thrombosis
Vascular Diseases
Thrombosis
Treatment
Thrombin generation assay
Clinical Study ID
NCT06094387
20230905-017-000
Ages 18-100 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≧ 18; AND
- Admitted to the mixed medical-surgical intensive care units of Queen Mary Hospital inHong Kong; AND
- Clinically indicated for central catheter insertion, which includes central venouscatheters and dialysis catheters; AND
- Expected to have the central catheter in place for at least 5 days in their ICU stay.
Exclusion
Exclusion Criteria:
- Patients known to have active venous thromboembolism including deep venous thrombosisor pulmonary embolism;
- Patients known to have hypercoagulable states, e.g., hereditary thrombophilia,antiphospholipid syndrome; OR
- Patients with active solid organ or hematological malignancies; OR
- Patients already receiving therapeutic anticoagulation prior to study recruitment; OR
- Patients with thrombosis detected in the insertion site before central catheterinsertion; OR
- Patients with a central venous catheter already in place prior to ICU admission; OR
- Patients admitted to the ICU for post-operative care; OR
- Patients admitted to the ICU for trauma care; OR
- Patients requiring extra-corporeal life support (ECLS); OR
- Patients with poor window or inaccessible for ultrasonographic examination; OR
- Pregnancy/post-partum within 6 weeks
Study Design
Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Thrombin generation assay
Phase:
Study Start date:
April 06, 2024
Estimated Completion Date:
April 01, 2025
Connect with a study center
Queen Mary Hospital
Hong Kong,
Hong KongActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.